Content
All Posts > Content under Pharma/Biotech
Research Report: AcelRx Pharmaceuticals (ACRX)
Article By:
Elle Investments
Read
Tuesday, May 26, 2020 1:12 PM EDT
Sales of sublingual sufentanil tablet Dsuvia have been slow out of the gate, but we remain very bullish on the long-term prospects.
In this article: ACRX
Allakos Drops After Regeneron Eosinophilic Esophagitis Study Hits Endpoints
TalkMarkets Tuesday Talk: May Market Maze
Article By:
TalkMarkets DailyTalk
Read
Tuesday, May 26, 2020 6:36 AM EDT
It's the last Tuesday in May and the start of a short trading week to end out the month, and what the week will look like is anyone's guess. With US-China tensions rising, a mix of good and bad news is sure to send the charts up and down.
Cannabis Central: Finally - The Pot Stock Marketplace Demystified
Article By:
Lorimer Wilson
Read
Tuesday, May 26, 2020 3:45 AM EDT
It is important to know which companies are doing business within each of the industry's 11 categories to make meaningful comparisons with their peers.
In this article: CGC, LQSIF, CRLBF, GWPH, CARA, ZYNE, NBEV, CRON, TLRY, PYX, ACB, APHA, CWBHF, ACRGF, YCBD, MEDIF, KERN, OGI, HUGE
What’s Next For The Biotech Bull Market? Are You A Trader Or An Investor?
Article By:
Rod Raynovich
Read
Tuesday, May 26, 2020 1:57 AM EDT
Despite the economic pains of the pandemic, investors are driven to life science companies in the news with potential solutions for COVID-19. The potential for a COVID-19 vaccine or a new viral diagnostic product has been the focus of the market.
In this article: BMY, MRK, RHHBY, FBIOX, IBB, ILMN, INCY, QQQ, REGN, SGEN, GILD, NBIX, PACB, VRTX, AMRN, GDX, XBI, XNCR, TDOC, EDIT, NTLA, CRSP, VIR, ABBV, PRHSX, IDXX
These Are Some Of The Coronavirus Vaccine Candidates
Sanofi To Sell Investment In Regeneron, Says Will Not Impact Collaboration
Bristol-Myers - A Strong Buy For Growth Income
Article By:
MoneyShow.com
Read
Monday, May 25, 2020 2:09 PM EDT
Bristol-Myers Squibb Company is a biopharmaceutical company with a mission to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases, asserts Crista Huff, editor of Cabot Undervalued Stocks Advisor.
S&P Futures Jump, Global Markets Rise In Holiday-Muted Session
Article By:
Tyler Durden
Read
Monday, May 25, 2020 8:50 AM EDT
US equity futures jumped in thin holiday volume, rising alongside European and Asian markets, and are now less than 20 points away from 3,000 having put the key resistance level of 2,950 in the rear view mirror.
Opening Day: SelectQuote Goes Public Amid COVID-19, Raises $360M In IPO
8 Monster Stocks To Watch For The Week Of May 25
Article By:
Michael J. Kramer
Read
Sunday, May 24, 2020 1:42 PM EDT
The market left itself in a vulnerable spot to start the final week of May. Trends overall are not all that bullish as the index continues to post signs of fading momentum.
Guardant Health: Strong Momentum And Enormous Opportunities
Article By:
Andres Cardenal
Read
Sunday, May 24, 2020 12:39 PM EDT
Guardant Health (GH) is a high growth business with enormous potential and truly disruptive technologies. A position in Guardant Health carries significant risks. However, the long term upside potential may well be worth the risk.
Weighing The Week Ahead: A Search For Balance In The Great Reopening
Article By:
Jeff Miller
Read
Sunday, May 24, 2020 3:57 AM EDT
The economic calendar features many important reports – housing, consumer confidence, personal income, personal spending, and the Fed’s Beige Book. We now have April data for economic reports and May data for confidence.
Profit From The Genomics Market Momentum With These ETFs
Article By:
Zacks Investment Research
Read
Saturday, May 23, 2020 7:04 PM EDT
It appears that growing demand for personalized medicine, solid investments and higher R&D activities can make genomics the next big thing in the investing space. We highlight a host of ETFs that investors can keep tabs on.